Cadrenal Therapeutics IncNASDAQ:CVKDNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4298
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.4000/ 5
- Ask / Lots0.4200/ 1
- Open / Previous Close0.0000 / 0.4298
- Day Range---
- 52 Week Range
- Volume168
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CVKD |
|---|---|---|
| 09:32 ET | 1042 | 0.43 |
| 09:34 ET | 943 | 0.4299 |
| 09:36 ET | 100 | 0.424 |
| 09:41 ET | 5000 | 0.42 |
| 09:45 ET | 940 | 0.4192 |
| 09:48 ET | 940 | 0.4177 |
| 09:59 ET | 1000 | 0.4149 |
| 10:03 ET | 15888 | 0.3996 |
| 10:10 ET | 39946 | 0.43 |
| 10:12 ET | 100 | 0.43 |
| 10:15 ET | 607 | 0.396 |
| 10:17 ET | 1350 | 0.3961 |
| 10:21 ET | 1000 | 0.3962 |
| 10:24 ET | 800 | 0.425 |
| 10:26 ET | 934 | 0.42 |
| 10:32 ET | 1000 | 0.4002 |
| 10:35 ET | 9000 | 0.4001 |
| 10:39 ET | 10000 | 0.4298 |
| 12:12 ET | 1000 | 0.4002 |
| 12:59 ET | 154 | 0.4161 |
| 01:12 ET | 101 | 0.4272 |
| 01:15 ET | 250 | 0.4161 |
| 01:57 ET | 100 | 0.42225 |
| 02:29 ET | 11075 | 0.4216 |
| 02:44 ET | 100 | 0.428 |
| 02:45 ET | 575 | 0.420001 |
| 03:05 ET | 1200 | 0.42 |
| 03:36 ET | 100 | 0.416 |
| 03:43 ET | 13953 | 0.43 |
| 03:48 ET | 100 | 0.4155 |
| 03:59 ET | 15642 | 0.4298 |
Apr 11, 2024
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024, from 4:30PM ET on Thursday Apr 11, 2024 by Dow Jones
4:30PM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 9, 2024
DJ Cadrenal Therapeutics Gets FDA Orphan Drug Designation for Tecarfarin, from 9:09AM ET on Tuesday Apr 09, 2024 by Dow Jones
9:09AM ET on Tuesday Apr 09, 2024 by Dow JonesCadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts, from 9:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
9:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cadrenal Therapeutics Inc | 6.9M | 0.0x | --- |
Company Information
Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.
Contact Information
- Headquarters
- 822 A1a North, Suite 300PONTE VEDRA, FL, United States 32082
- Phone
- 904-300-0701
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Quang Pham
- Chief Financial Officer
- Matthew Szot
- Chief Medical Officer
- Douglas Losordo
- Independent Director
- John Murphy
- Independent Director
- Glynn Wilson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.9M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 16.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | --- |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
